ES2226792T3 - El uso de derivados de 4-h-1-benzopiran-4-ona como inhibidores de la proliferacion de miocitos lisos. - Google Patents

El uso de derivados de 4-h-1-benzopiran-4-ona como inhibidores de la proliferacion de miocitos lisos.

Info

Publication number
ES2226792T3
ES2226792T3 ES00909918T ES00909918T ES2226792T3 ES 2226792 T3 ES2226792 T3 ES 2226792T3 ES 00909918 T ES00909918 T ES 00909918T ES 00909918 T ES00909918 T ES 00909918T ES 2226792 T3 ES2226792 T3 ES 2226792T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
flavopyridol
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00909918T
Other languages
English (en)
Spanish (es)
Inventor
Winston Campbell Patterson
Jennifer A. Dumont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
University of Texas System
University of Texas at Austin
Original Assignee
Aventis Pharmaceuticals Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc, University of Texas System, University of Texas at Austin filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2226792T3 publication Critical patent/ES2226792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES00909918T 1999-02-01 2000-01-18 El uso de derivados de 4-h-1-benzopiran-4-ona como inhibidores de la proliferacion de miocitos lisos. Expired - Lifetime ES2226792T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US243380 1988-09-12
US24338099A 1999-02-01 1999-02-01
US468665 1999-12-21
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (1)

Publication Number Publication Date
ES2226792T3 true ES2226792T3 (es) 2005-04-01

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00909918T Expired - Lifetime ES2226792T3 (es) 1999-02-01 2000-01-18 El uso de derivados de 4-h-1-benzopiran-4-ona como inhibidores de la proliferacion de miocitos lisos.

Country Status (38)

Country Link
US (1) US6399633B1 (enExample)
EP (1) EP1150746B1 (enExample)
JP (1) JP4755759B2 (enExample)
KR (1) KR100793047B1 (enExample)
CN (1) CN1219556C (enExample)
AP (1) AP1469A (enExample)
AR (1) AR042569A1 (enExample)
AT (1) ATE275428T1 (enExample)
AU (1) AU777368B2 (enExample)
BG (1) BG65151B1 (enExample)
BR (1) BR0007911A (enExample)
CA (1) CA2360668C (enExample)
CR (1) CR6448A (enExample)
CZ (1) CZ300395B6 (enExample)
DE (1) DE60013555T2 (enExample)
DK (1) DK1150746T3 (enExample)
EA (1) EA004786B1 (enExample)
EE (1) EE04851B1 (enExample)
ES (1) ES2226792T3 (enExample)
HK (1) HK1042445B (enExample)
HR (1) HRP20010521A2 (enExample)
HU (1) HU229263B1 (enExample)
ID (1) ID30180A (enExample)
IL (1) IL144668A (enExample)
ME (1) MEP10508A (enExample)
NO (1) NO330512B1 (enExample)
NZ (1) NZ512822A (enExample)
OA (1) OA11755A (enExample)
PL (1) PL197693B1 (enExample)
PT (1) PT1150746E (enExample)
RS (1) RS50242B (enExample)
SI (1) SI1150746T1 (enExample)
SK (1) SK286747B6 (enExample)
TR (1) TR200102223T2 (enExample)
TW (1) TWI273907B (enExample)
UA (1) UA73110C2 (enExample)
WO (1) WO2000044362A2 (enExample)
ZA (1) ZA200105596B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
DK1511734T3 (da) * 2002-04-17 2010-08-02 Cytokinetics Inc Forbindelser, præparater og fremgangsmåder
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20100068238A1 (en) * 2005-07-15 2010-03-18 Nandkishore Managoli Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
KR101374983B1 (ko) 2006-08-28 2014-03-17 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
EP2346837B8 (en) 2008-06-26 2015-04-15 Resverlogix Corporation Methods of preparing quinazolinone derivatives
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CN102427813A (zh) 2009-03-18 2012-04-25 雷斯韦洛吉克斯公司 新的抗炎剂
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
US20130225530A1 (en) 2010-07-12 2013-08-29 Dkfz Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2773354B1 (en) 2011-11-01 2019-06-12 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
HUE056325T2 (hu) 2013-08-26 2022-02-28 Biontech Res And Development Inc SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3154583T (pt) 2014-06-04 2021-03-24 Biontech Res And Development Inc Anticorpos monoclonais humanos para o gangliósido gd2
TN2017000246A1 (en) 2014-12-11 2018-10-19 Pf Medicament Anti-c10orf54 antibodies and uses thereof
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
RU2717829C2 (ru) 2015-04-20 2020-03-26 Толеро Фармасьютикалз, Инк. Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
PT3298021T (pt) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
US10875920B2 (en) 2015-12-02 2020-12-29 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
RU2769251C2 (ru) 2016-08-23 2022-03-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения гепатоцеллюлярной карциномы
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3595725B1 (en) 2017-03-16 2023-05-03 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
AU2018277838C1 (en) 2017-05-31 2025-08-07 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3694889A1 (en) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Human antibodies to thomsen-nouvelle (tn) antigen
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
EP3890749B1 (en) 2018-12-04 2025-10-29 Sumitomo Pharma America, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘

Also Published As

Publication number Publication date
SI1150746T1 (en) 2005-02-28
JP2002535356A (ja) 2002-10-22
MEP10508A (en) 2010-06-10
NZ512822A (en) 2005-01-28
CZ20012804A3 (cs) 2002-08-14
DE60013555T2 (de) 2005-09-29
US6399633B1 (en) 2002-06-04
PL197693B1 (pl) 2008-04-30
CR6448A (es) 2004-03-17
YU54401A (sh) 2004-05-12
HK1042445B (zh) 2006-01-13
DE60013555D1 (de) 2004-10-14
DK1150746T3 (da) 2005-01-10
HRP20010521A2 (en) 2002-08-31
EE200100385A (et) 2002-12-16
SK286747B6 (sk) 2009-04-06
NO20013335D0 (no) 2001-07-05
AP1469A (en) 2005-09-26
EP1150746A2 (en) 2001-11-07
WO2000044362A2 (en) 2000-08-03
BG65151B1 (bg) 2007-04-30
BR0007911A (pt) 2001-10-16
EA004786B1 (ru) 2004-08-26
AP2001002218A0 (en) 2001-09-30
WO2000044362A3 (en) 2001-04-05
ID30180A (id) 2001-11-08
BG105751A (en) 2002-02-28
AR042569A1 (es) 2005-06-29
CN1338958A (zh) 2002-03-06
UA73110C2 (en) 2005-06-15
KR20010093309A (ko) 2001-10-27
TWI273907B (en) 2007-02-21
HUP0200804A2 (hu) 2002-12-28
TR200102223T2 (tr) 2004-12-21
OA11755A (en) 2005-07-19
CN1219556C (zh) 2005-09-21
NO20013335L (no) 2001-09-25
PT1150746E (pt) 2004-12-31
AU777368B2 (en) 2004-10-14
HK1042445A1 (en) 2002-08-16
EP1150746B1 (en) 2004-09-08
RS50242B (sr) 2009-07-15
ZA200105596B (en) 2002-10-07
HU229263B1 (en) 2013-10-28
CA2360668C (en) 2009-03-17
KR100793047B1 (ko) 2008-01-10
SK10862001A3 (sk) 2002-07-02
CA2360668A1 (en) 2000-08-03
HUP0200804A3 (en) 2004-03-29
NO330512B1 (no) 2011-05-09
EA200100742A1 (ru) 2001-12-24
ATE275428T1 (de) 2004-09-15
JP4755759B2 (ja) 2011-08-24
CZ300395B6 (cs) 2009-05-06
IL144668A0 (en) 2002-05-23
PL350735A1 (en) 2003-01-27
AU3209800A (en) 2000-08-18
EE04851B1 (et) 2007-06-15
IL144668A (en) 2005-06-19

Similar Documents

Publication Publication Date Title
ES2226792T3 (es) El uso de derivados de 4-h-1-benzopiran-4-ona como inhibidores de la proliferacion de miocitos lisos.
US6887853B2 (en) Use of geldanamycin and related compounds for treatment of fibrogenic disorders
Zhu et al. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss
US10214491B2 (en) Activators and therapeutic applications thereof
US6495586B2 (en) Scytonemin and methods of using thereof
MXPA01007278A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
KR101734937B1 (ko) ERRγ 역작동제를 유효성분으로 함유하는 암의 치료를 위한 방사성 요오드 요법에 적용되는 효능 증진제
US6495588B2 (en) Scytonemin and methods of using thereof
CN119630646A (zh) Tead靶向化合物及其方法
Eastman p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?